Articles tagged with 'VI' | BIOTRONIK

BIOTRONIK - Archive (VI)

2020
06
May
2020
| 09:24 Europe/Amsterdam
According to recently presented TICO trial data, patients with acute coronary syndrome (ACS) treated with BIOTRONIK’s Orsiro® drug eluting stent (DES) benefit from stopping aspirin three months after stenting and continuing only with ticagrelor monot...
Read more
24
February
2020
| 00:00 Europe/Amsterdam
BIOTRONIK today announced three-year data from the BIOFLOW-V trial, which was presented yesterday at the 2020 CRT Congress. The three-year follow-up data demonstrates consistently lower clinical event rates and improvement in patient outcomes, reinfo...
Read more
21
February
2020
| 14:11 Europe/Amsterdam
BIOTRONIK has announced CE Mark certification for the Orsiro® Mission drug-eluting stent (DES) system. The next generation of the company’s ultrathin strut Orsiro DES provides higher deliverability than other contemporary stents.1 Orsiro Mission is n...
Read more
2019
30
October
2019
| 00:00 Europe/Amsterdam
BIOTRONIK announced today that its Orsiro® coronary drug-eluting stent (DES) has been approved for sale in China by the National Medical Products Administration. The company expects to make the device available to Chinese patients and physicians in t...
Read more
18
October
2019
| 14:54 Europe/Amsterdam
  About 30 percent of patients undergoing primary percutaneous coronary intervention (PCI) suffer from ST-Elevation Myocardial Infarction (STEMI) – the most acute form of coronary artery disease. It’s caused by a complete thrombotic occlusion and ...
Read more
30
September
2019
| 00:00 Europe/Amsterdam
Full cohort data from the BIOSOLVE-IV registry strengthen the clinical evidence for BIOTRONIK’s Magmaris®1 Resorbable Magnesium Scaffold (RMS) as a therapy option for patients with coronary artery disease. Dr. Stefan Verheye, Senior Interventional Ca...
Read more
11
September
2019
| 00:00 Europe/Amsterdam
Twelve-month results of the BIOFLEX COF trial have demonstrated that the implantation of stents with low chronic outward force1 (COF) was associated with less neointimal hyperplasia2, consequently resulting in less restenosis. Patients treated with B...
Read more
02
September
2019
| 00:00 Europe/Amsterdam
BIOTRONIK’s ultrathin Orsiro® stent demonstrated superiority over Xience with respect to target lesion failure (TLF) at 12 months, according to newly released data from the BIOSTEMI trial.1 Today Dr. Juan Fernando Iglesias, Geneva University Hospital...
Read more
31
July
2019
| 00:00 Europe/Amsterdam
BIOTRONIK today announced the company’s PK Papyrus® covered coronary stent system1 has been named a finalist in the 2019 Prix Galien USA Awards Ceremony for Best Medical Technology. PK Papyrus is used in emergency situations to create a physical b...
Read more
07
June
2019
| 00:00 Europe/Amsterdam
New data from the BIOSOLVE-IV registry strengthen the clinical evidence for the Magmaris®1 resorbable scaffold device and procedure success and safety profile at one year. Dr. Stefan Verheye, Senior Interventional Cardiologist at Antwerp Cardiovascul...
Read more
21
May
2019
| 00:00 Europe/Amsterdam
Focusing on patients with small vessels, three-year outcomes of the BIO-RESORT randomized controlled trial (RCT) showed a significantly lower target lesion revascularization (TLR) rate and thus better efficacy of the Orsiro® drug-eluting stent1 (DES)...
Read more
18
April
2019
| 00:00 Europe/Amsterdam
BIOLUX P-III 24-month study data supports safe and effective clinical performance of the Passeo®-18 LuxTM drug-coated balloon (DCB) for patients with infrapopliteal artery lesions and in-stent restenosis (ISR). The full BIOLUX P-III study cohort comp...
Read more
10
April
2019
| 00:00 Europe/Amsterdam
BIOTRONIK today announced the United States (US) commercial launch of the PK Papyrus® covered coronary stent system for use in the emergency treatment of acute coronary perforations.1,2 More than 800,000 percutaneous coronary intervention procedur...
Read more
10
April
2019
| 00:00 Europe/Amsterdam
BIOTRONIK launched today the Carnelian®1 Support catheter,2 designed to improve the access for treatment of tortuous and highly calcified lesions. Carnelian Support is indicated for the exchange and support of guidewires into peripheral vasculature.3...
Read more
06
March
2019
| 00:00 Europe/Amsterdam
Three-year outcome data from the BIO-RESORT1 randomized controlled trial were presented in a late-breaking clinical trials session by Dr. Clemens von Birgelen, Thoraxcentrum Twente, MST, Enschede, The Netherlands. Results from this large three-arm tr...
Read more
05
March
2019
| 00:00 Europe/Amsterdam
Preliminary data from the BIOSOLVE-IV registry strengthen the clinical evidence in favor of BIOTRONIK’s resorbable magnesium scaffold Magmaris®1 for de novo coronary artery lesions. Presented as late-breaking clinical data at the Cardiovascular Resea...
Read more
25
February
2019
| 00:00 Europe/Amsterdam
BIOTRONIK today announced FDA approval of the Orsiro drug-eluting stent (DES) system. Orsiro is the first and only ultrathin DES to outperform the clinical standard, Xience.1,2 Orsiro received CE marking in 2011 and has been used to treat more than o...
Read more
12
February
2019
| 00:00 Europe/Amsterdam
Data from the BIOLUX P-III All-Comers Registry presented at LINC 2019 highlighted the safety and efficacy of BIOTRONIK’s Passeo-18 Lux* drug-coated balloon (DCB), even in challenging patient subgroups. A number of presentations during LINC congress f...
Read more
22
January
2019
| 00:00 Europe/Amsterdam
BIOTRONIK presented the innovative Pulsar-18 T3 stent system for the first time during LINC 2019 in Leipzig this week. The Pulsar-18 T3 system is a unique combination of three technologies for an improved implantation procedure. The 4-French low p...
Read more
2018
20
November
2018
| 00:00 Europe/Amsterdam
Following a statistical calculation error, the outcomes of SORT-OUT IX1 have recently been corrected, resulting in a change to the trial’s primary endpoint. The revised data analysis demonstrates that compared to BIOTRONIK’s Orsiroa drug-eluting sten...
Read more
28
September
2018
| 00:00 Europe/Amsterdam
During this year’s CIRSE congress, Prof. Christoph Binkert, Kantonsspital Winterthur, Switzerland, presented 24-month outcomes of the world’s second largest Real-World DCB registry, BIOLUX P-III. Data presented included the 24-month outcomes of the S...
Read more
25
September
2018
| 00:00 Europe/Amsterdam
Investigators unveiled clinical data from the independent BIONYX1 and SORT OUT IX2 all-comers trials which respectively compared durable polymer Resolute Onyxb and polymer-free BioFreedomc to bioresorbable polymer Orsiro. In both studies, patients...
Read more
24
September
2018
| 00:00 Europe/Amsterdam
Preliminary data from BIOSOLVE-IV registry shows low target lesion failure (TLF) rates of 4.3% with Magmarisa and only one case of scaffold thrombosis (after DAPT interruption before the event).1 The data presented at the TCT congress as late-brea...
Read more
24
September
2018
| 00:00 Europe/Amsterdam
Today, BIOTRONIK announced two-year data from the BIOFLOW-V randomized trial comparing the Orsiro and Xience1 drug-eluting stents (DES). The data shows statistically improved outcomes for patients treated with Orsiro across a range of clinical endpoi...
Read more
14
September
2018
| 00:00 Europe/Amsterdam
BIOTRONIK today announced the FDA approval of the PK Papyrus covered coronary stent system under Humanitarian Device Exemption for use in the emergency treatment of acute coronary perforations.1,2 PK Papyrus received CE marking in 2013. Built on B...
Read more
14
June
2018
| 00:00 Europe/Amsterdam
Ever since its CE launch in June 2016, BIOTRONIK’s Magmaris has been implanted by more than 650 physicians in over 350 hospitals across 45 countries. As part of its Magnesium 2,000 program, a post-market evaluation program, more than 2,000 Magmaris c...
Read more
24
May
2018
| 00:00 Europe/Amsterdam
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials session by Dr. Marlies M. Kok, Thoraxcentrum Twente, MST, Enschede, the Netherlands and simultaneously published in EuroInterventi...
Read more
Tags
PR
VI
23
May
2018
| 00:00 Europe/Amsterdam
Data presented during the EuroPCR congress on the Magmaris Resorbable Magnesium Scaffold (RMS) provide further evidence on its continued safety and efficacy, also in a more complex population. Dr. Stefan Verheye, M.D., Ph.D., Senior Interventional...
Read more
27
March
2018
| 00:00 Europe/Amsterdam
Dr. Yang Yue Jin, Professor of Cardiology at the Fu-Wai Hospital, National Center of Cardiovascular Disease, Beijing, China, presented the 9- and 12-month results of the BIOFLOW-VI clinical study at the China Interventional Therapeutics (CIT) 2018 co...
Read more
13
March
2018
| 00:00 Europe/Amsterdam
BIOTRONIK announced today that patient enrollment for the BIOSTEMI study has been completed. STEMI is a potentially fatal type of heart attack, caused by prolonged obstruction of blood supply in the heart. More than 730,000 cardiac artery disease (CA...
Read more